Inactive Instrument

Aroa Biosurgery Limited Share Price Australian S.E.

Equities

ARX

AU0000094146

Medical Equipment, Supplies & Distribution

Financials

Sales 2025 * 8.52Cr 5.18Cr 7.77Cr 431.94Cr Sales 2026 * 11Cr 6.63Cr 9.94Cr 552.57Cr Capitalization 23Cr 14Cr 21Cr 1.14TCr
Net income 2025 * - 0 0 0 Net income 2026 * 90L 54.76L 82.1L 46Cr EV / Sales 2025 * 2.31 x
Net cash position 2025 * 2.86Cr 1.74Cr 2.61Cr 145.18Cr Net cash position 2026 * 3.21Cr 1.96Cr 2.93Cr 162.94Cr EV / Sales 2026 * 1.77 x
P/E ratio 2025 *
-334 x
P/E ratio 2026 *
24.3 x
Employees -
Yield 2025 *
-
Yield 2026 *
0.51%
Free-Float 72.87%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 01/08/01
Director of Finance/CFO - 01/13/01
Chief Tech/Sci/R&D Officer - 01/13/01
Members of the board TitleAgeSince
Director/Board Member - 05/08/05
Director/Board Member 58 01/15/01
Director/Board Member - 21/19/21
More insiders
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.
Calendar
More about the company